Literature DB >> 27094611

Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia.

Ewa M Kosciuczuk1, Diana Saleiro2, Leonidas C Platanias3.   

Abstract

Dysregulation of mRNA translation leads to aberrant activation of cellular pathways that promote expansion and survival of leukemic clones. A key element of the initiation translation complex is eIF4E (eukaryotic translation initiation factor 4E). The mitogen-activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR) pathways play important roles in the regulation of eIF4E expression and downstream functional outcomes. Mitogen-activated protein kinase interacting protein kinases (Mnks) control translation by phosphorylation of eIF4E, whereas the mTOR kinase phosphorylates/de-activates the eIF4E inhibitor, 4E-BP1, to release translational repression. Both pathways are often abnormally activated in leukemia cells and promote cell survival events by controlling expression of oncogenic proteins. Targeting these pathways may provide approaches to avoid aberrant proliferation and neoplastic transformation. Published by Elsevier Ltd.

Entities:  

Keywords:  Acute myeloid leukemia; MNK; Translation initiation; eIF4E; mTOR

Mesh:

Substances:

Year:  2016        PMID: 27094611      PMCID: PMC5065931          DOI: 10.1016/j.cyto.2016.01.024

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  93 in total

1.  Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities.

Authors:  Ivan Topisirovic; Melisa Ruiz-Gutierrez; Katherine L B Borden
Journal:  Cancer Res       Date:  2004-12-01       Impact factor: 12.701

2.  Lack of antileukemic activity of rapamycin in elderly patients with acute myeloid leukemia evolving from a myelodysplastic syndrome.

Authors:  Fernando Callera; Carlos O Lopes; Evandro S Rosa; Carla C Mulin
Journal:  Leuk Res       Date:  2008-04-10       Impact factor: 3.156

3.  Mnk kinases in cytokine signaling and regulation of cytokine responses.

Authors:  Sonali Joshi; Leonidas C Platanias
Journal:  Biomol Concepts       Date:  2015-03

4.  Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.

Authors:  Sarah Diab; Theodosia Teo; Malika Kumarasiri; Peng Li; Mingfeng Yu; Frankie Lam; Sunita K C Basnet; Matthew J Sykes; Hugo Albrecht; Robert Milne; Shudong Wang
Journal:  ChemMedChem       Date:  2014-02-12       Impact factor: 3.466

5.  RAD001 (everolimus) enhances TRAIL cytotoxicity in human leukemic Jurkat T cells by upregulating DR5.

Authors:  Myoung Woo Lee; Dae Seong Kim; Ji-Eun Eom; Young Jong Ko; Ki Woong Sung; Hong Hoe Koo; Keon Hee Yoo
Journal:  Biochem Biophys Res Commun       Date:  2015-06-12       Impact factor: 3.575

6.  Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.

Authors:  Nicolas Chapuis; Jerome Tamburini; Alexa S Green; Christine Vignon; Valerie Bardet; Aymeric Neyret; Melanie Pannetier; Lise Willems; Sophie Park; Alexandre Macone; Sauveur-Michel Maira; Norbert Ifrah; François Dreyfus; Olivier Herault; Catherine Lacombe; Patrick Mayeux; Didier Bouscary
Journal:  Clin Cancer Res       Date:  2010-09-30       Impact factor: 12.531

Review 7.  Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.

Authors:  Nushmia Z Khokhar; Jessica K Altman; Leonidas C Platanias
Journal:  Curr Opin Oncol       Date:  2011-11       Impact factor: 3.645

8.  Characterization of the activity of human MAP kinase-interacting kinase Mnk1b.

Authors:  Ana O'Loghlen; Víctor M González; Teresa Jurado; Matilde Salinas; M Elena Martín
Journal:  Biochim Biophys Acta       Date:  2007-05-29

9.  Discovery of cercosporamide, a known antifungal natural product, as a selective Pkc1 kinase inhibitor through high-throughput screening.

Authors:  Andrea Sussman; Karen Huss; Li-Chun Chio; Steve Heidler; Margaret Shaw; Doreen Ma; Guoxin Zhu; Robert M Campbell; Tae-Sik Park; Palaniappan Kulanthaivel; John E Scott; John W Carpenter; Mark A Strege; Matthew D Belvo; James R Swartling; Anthony Fischl; Wu-Kuang Yeh; Chuan Shih; Xiang S Ye
Journal:  Eukaryot Cell       Date:  2004-08

10.  Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.

Authors:  Seiichi Okabe; Tetsuzo Tauchi; Yuko Tanaka; Toshihiko Kitahara; Shinya Kimura; Taira Maekawa; Kazuma Ohyashiki
Journal:  Cancer Biol Ther       Date:  2013-11-08       Impact factor: 4.742

View more
  10 in total

1.  MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma.

Authors:  Yao Zhan; Jun Guo; William Yang; Christophe Goncalves; Tomasz Rzymski; Agnieszka Dreas; Eliza Żyłkiewicz; Maciej Mikulski; Krzysztof Brzózka; Aniela Golas; Yan Kong; Meng Ma; Fan Huang; Bonnie Huor; Qianyu Guo; Sabrina Daniela da Silva; Jose Torres; Yutian Cai; Ivan Topisirovic; Jie Su; Krikor Bijian; Moulay A Alaoui-Jamali; Sidong Huang; Fabrice Journe; Ghanem E Ghanem; Wilson H Miller; Sonia V Del Rincón
Journal:  J Clin Invest       Date:  2017-10-16       Impact factor: 14.808

2.  Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo.

Authors:  Ewa M Kosciuczuk; Diana Saleiro; Barbara Kroczynska; Elspeth M Beauchamp; Frank Eckerdt; Gavin T Blyth; Sameem M Abedin; Francis J Giles; Jessica K Altman; Leonidas C Platanias
Journal:  Blood       Date:  2016-06-15       Impact factor: 22.113

3.  Modulation of the p53 family network by RNA-binding proteins.

Authors:  Chris Lucchesi; Jin Zhang; Xinbin Chen
Journal:  Transl Cancer Res       Date:  2016-12       Impact factor: 1.241

4.  Insulin Directs Dichotomous Translational Regulation to Control Human Pluripotent Stem Cell Survival, Proliferation and Pluripotency.

Authors:  Xiaoxiao Zhou; Zhili Ren; Jiaqi Xu; Chunhao Deng; Zhaoying Zhang; Carlos Godoy-Parejo; Faxiang Xu; Esther Chi Cheng Huang; Jiajia Wang; Zheyu Cai; Weiwei Liu; Guang Hu; Guokai Chen
Journal:  Int J Biol Sci       Date:  2022-05-16       Impact factor: 10.750

5.  Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy.

Authors:  S Liu; J Zha; M Lei
Journal:  Clin Transl Oncol       Date:  2017-08-01       Impact factor: 3.405

6.  Genetic and pharmacological inhibition of eIF4E effectively targets esophageal cancer cells and augments 5-FU's efficacy.

Authors:  Jindan Kai; Yiqiao Wang; Fei Xiong; Sheng Wang
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

Review 7.  Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update.

Authors:  Camilla Evangelisti; Francesca Chiarini; James A McCubrey; Alberto M Martelli
Journal:  Int J Mol Sci       Date:  2018-06-26       Impact factor: 5.923

8.  Sodium butyrate and panobinostat induce apoptosis of chronic myeloid leukemia cells via multiple pathways.

Authors:  Xiaoyuan Jia; Yinsuo Zheng; Yanzi Guo; Kan Chen
Journal:  Mol Genet Genomic Med       Date:  2019-03-19       Impact factor: 2.183

9.  Inhibitory effects of SEL201 in acute myeloid leukemia.

Authors:  Ewa M Kosciuczuk; Aroop K Kar; Gavin T Blyth; Mariafausta Fischietti; Sameem Abedin; Alain A Mina; Rebekah Siliezar; Tomasz Rzymski; Krzysztof Brzozka; Elizabeth A Eklund; Elspeth M Beauchamp; Frank Eckerdt; Diana Saleiro; Leonidas C Platanias
Journal:  Oncotarget       Date:  2019-12-24

10.  Integrative resource for network-based investigation of COVID-19 combinatorial drug repositioning and mechanism of action.

Authors:  A K M Azad; Shadma Fatima; Alexander Capraro; Shafagh A Waters; Fatemeh Vafaee
Journal:  Patterns (N Y)       Date:  2021-07-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.